Himanshu Bhavsar

🌍 India at the Crossroads of Global Pharma Realignment On October 3, the U.S. FDA https://lnkd.in/gjGdgri2 unveiled a bold pilot — fast-tracking generic drug reviews when the entire chain — from API sourcing to bioequivalence testing to final manufacturing — occurs within the U.S. This isn’t just regulatory tinkering. It’s a strategic push to re-industrialize, reclaim sovereignty over drug security, and shift the center of gravity in global pharma. U.S. media https://lnkd.in/gjNuqCAJ frames this as both an economic and national security move. The implication? Countries like India, which currently supply large APIs and lead in generics, face the dual challenge of preserving export markets while forging new paths into U.S. territory. The Indian Pharmaceutical Alliance https://lnkd.in/g_rQQY_e has already pushed back against tariff rhetoric, defending the quality and global trust Indian firms have built. But here lies a deeper narrative — India is not merely a supplier but a strategic partner — one that must transform itself or risk being sidelined. Greater capital tie-ups in U.S. soil, joint ventures, dual-market facilities, and shared compliance regimes will no longer be optional — they’ll be essential. This moment calls not for reaction, but reflection and reinvention. As global pharma dynamics shift, India’s strength lies not just in scale — but in foresight, collaboration, and trust. 💭 How can we, as stakeholders, innovators, and policymakers, reimagine India’s role from being the ‘pharmacy of the world’ to becoming the ‘engine of global health resilience’? The answers will shape the next decade of medicine — and they must come from all of us. — Chakravarthi AVPS #IndiaPharma #PharmaStrategy #GlobalHealth #FDAPilot #DrugSecurity #globalpharma #HealthcareLeadership #SupplyChainResilience #Innovation #PolicyInsight

76

3 Comments

In 2016, this 500CR pharma brand almost got killed because of a packaging decision. Here's what happened: A well-known Indian pharma company (let’s call them Company X) was dominating the antibiotic space. Their top-performing molecule was hitting ~₹500 Cr annually. Then one quarter, sales started slipping. Not in double digits, but enough to raise eyebrows. Doctors were still prescribing. Distributors weren’t complaining. No new competition had entered the market. So what went wrong? They had changed the strip design. From a deep red blister to a pale white one. No other change... same formulation, same price, same everything. But at the chemist level, here’s what happened: 💬 "Yeh toh doosri company ka lag raha hai.” 💬 “Original wali packing nahi hai kya?” 💬 “Patient ko trust nahi aata is strip pe.” That small change created confusion in brand recall. And when patients hesitated, chemists switched. In a fragmented market, packaging = trust. And trust = sales. The fix? They immediately reverted to the old packaging. Ran a targeted communication campaign for chemists and doctors. Even added QR codes to assure authenticity. Within 2 quarters, the brand was back on track. In pharma, perception is power. Even something as “small” as color can cost crores. If you’re in pharma marketing or sales, never ignore the frontline feedback. Whether it's from a rural chemist or an anxious patient. That’s where your real market intelligence lives. -- 👉 Follow me for more such pharma marketing breakdowns.

190

28 Comments

Dr. Bindu Menon: A Ray of Hope for Rural Healthcare 🌿👩‍⚕️ For years, Dr. Bindu Menon, a well-known neurologist, has been carrying her mission of free healthcare into the villages of India. Through her regular medical camps, she has reached thousands of people who otherwise had no access to specialized treatment, offering not just medicines but also comfort and dignity to those in need. Service Beyond the City 🏥💛 Although she practices in city hospitals, Dr. Menon was always troubled by the gap between urban and rural healthcare. Determined to reduce this divide, she began traveling to remote villages to organize free health camps. In each camp, she doesn’t stop at treatment alone — she also teaches villagers to identify early symptoms of disease and to seek help before it is too late. Neurological Care for the Forgotten 🧠💊 Her focus lies on conditions like epilepsy, stroke, migraine, and Parkinson’s disease, which are rarely diagnosed in rural communities. Along with her team, she provides check-ups, distributes free medicines, and ensures follow-up care so that patients continue to receive support even after the camp. Bridging Gaps with Technology 📱🔗 To make her service more accessible, she launched a mobile app and helpline, enabling patients in far-off villages to consult her without traveling long distances. This step has brought continuous care within everyone’s reach. ✨ An Inspiration to All ✨ Dr. Bindu Menon’s work is more than medical service — it is a call for equality in healthcare. Her vision is simple: every Indian deserves timely treatment, no matter where they live. 🙏 #BinduMenon #HealthcareForAll #Inspiration #TrueHero #ChangeMaker

2,965

48 Comments

For those who buy medicines every month, every rupee counts. The new and revised GST slabs are a progressive and positive step towards easing the financial burden on patients and families who are already navigating the challenges of long-term treatment. Here’s what’s changed: - 0% GST on 33 life-saving drugs, including several cancer and rare-disease therapies. Earlier, this used to be 12%. - The GST on all other drugs and medicines has been reduced from 12% to a more affordable 5%. - An array of medical devices and supplies, including surgical equipment, dental apparatus, diagnostic kits, and common items like glucometers and bandages, will now attract a GST rate of 5%, down from the earlier rates of 12%. A much-needed relief, I must say 🙏

94

3 Comments

9 Jewel Pharmaceutical Companies in India with Global Presence India's pharmaceutical industry is making significant waves globally, with several companies leading the charge. Here are 9 notable pharmaceutical companies in India with a strong global presence I have been narrated about India's Navaratna Companies Like few ONGC BHEL NALCO etc Where not a Single Pharma Company features Though we Have Few Govt Companies But not like Public limited Govt Companies of India Like Hindustan Antibiotics Bengal Chemicals IDPLEtc However the following are 9 Jewels Pvt Pharma Companies. 1- Top Players - Sun Pharmaceutical Industries Ltd India's largest pharmaceutical company with operations in over 100 countries. 2 - Dr. Reddy's Laboratories A leading innovator with presence in over 40 countries. 3 - Cipla Ltd Known for affordable, high-quality pharmaceuticals in over 80 countries. 4 - Lupin Pharmaceuticals Ltd Global leader in generics and specialty medicines. 5 - Aurobindo Pharma Ltd Major players in global pharmaceuticals with presence in over 150 countries. 6 -Cadila Healthcare (Zydus Cadila) Innovation-driven with global presence. 7 - Torrent Pharmaceuticals Focus on research and development with global reach. 8 - Glenmark Pharmaceuticals Research-driven presence in over 80 countries. 9 - Alkem Laboratories Formulations in various therapeutic areas with exports to over 70 countries. #indianpharmamanufacturers# #globalindiahealthmission# #indianpharmaranddhouses# #indianpharmaexporters# #leadingindianpharmacompanies#

209

14 Comments

GST Reform & Healthcare: A Step Toward Affordability? The revised GST framework effective September 22 simplifies rates to Nil, 5%, 18% and 40%. For healthcare, three changes stand out: 1️⃣ Medical essentials at lower rates – Thermometers, medical oxygen, test kits, devices, and spectacles now fall from 12–18% to 5%. This directly reduces the cost burden for patients. 2️⃣ Insurance at nil – Health and life insurance now attract no GST. This could accelerate penetration, especially in Tier II and Tier III cities where affordability has long been a barrier. 3️⃣ Compliance simplified – Streamlining into four slabs reduces administrative complexity for pharma and medtech companies. For an industry already navigating stringent GMP, GCP, and GDP regulations, this matters. But the bigger picture? Lower GST doesn’t just make products cheaper. It can improve adherence, drive wider insurance coverage, and ease compliance costs for the ecosystem. The real test will be in execution. Will lower device costs translate into deeper rural access? Will nil GST insurance drive mass adoption or remain urban centric? Will simplified slabs reduce disputes and bottlenecks for pharma manufacturers? For me, this reform is less about tax slabs and more about strengthening the affordability and access loop in healthcare. 📌 As we move forward, one thing is clear. Policy design and industry action must converge to make these benefits visible at the patient level. For pharma leaders and policymakers, how do you see GST shaping affordability and compliance over the next 2–3 years? (Reference: Ministry of Finance release, Angel One report, 2025)

204

13 Comments

Rethinking Doctor-Patient Interactions in #India: Lessons from Abroad The doctor-patient relationship is the cornerstone of #healthcare, yet in India, it often feels like a vastly different experience compared to what we see overseas. Having experienced both, I’ve often pondered why these discrepancies exist and what we can learn to enhance our healthcare journey. The Indian Healthcare Journey: A Closer Look   1. The Follow-Up Void: In India, patient follow-ups are surprisingly rare. Once you leave the clinic, you're often on your own, lacking continued guidance. 2. The Missing #Pharmacist as an Ally: Unlike many Western countries where pharmacists play a vital role as continuing advisors, this essential layer of support is largely absent in India. Patients are often left feeling truly abandoned once they have their #medication. 3. The Waiting Game: Who hasn't spent an inordinate amount of time waiting in a doctor's clinic? Why can't we streamline appointments for a more respectful use of everyone's time? This applies to both patients and doctors. 4. Perfunctory #Examinations & Lack of #Transparency: There's a perception that examinations can be brief and superficial. More critically, detailed written reports of findings and observations are rarely provided. When they are, they’re often in handwriting that even a seasoned cryptographer would struggle with! This creates significant hurdles for chemists trying to dispense the right medicine. In Western countries, doctors are often diligently recording notes on computers, summarising discussions, and providing clear recommendations and follow-up actions. Empowering #patients with a better understanding of their condition & treatment plan. The "why" behind findings and recommendations is also explained, fostering #trust and clarity. 1. To get more time from your doctor: A #solution is to take back-to-back appointment as double appointment. This gives extra time for meaningful dialogue or a thorough consultation. 2. Seek Second Opinions: For various reasons, seeking second or third opinion is not as common, which can limit comprehensive care. 3. Pharmacy Predicaments: Even if we manage to decipher the doctor’s handwriting, challenges don't end there. Anecdotally, many of us have received a different brand of medicine than prescribed, even if the chemical composition is the same. This practice, often driven by higher margins for the pharmacy, raises concerns about quality and patient choice, and directly impacts pharmaceutical companies whose products are substituted. Consider this striking statistic: In Western hospitals, over 15% of occupied beds are filled by patients admitted due to incorrect prescriptions, improper administration, or medication malfunctions. Has anyone genuinely investigated the scale of this issue in India? What have your experiences been, and what are your thoughts on enhancing our healthcare interactions?

83

4 Comments

🚀 ABFRL: A Story of Scale, Style & Smart Acquisitions Aditya Birla Fashion and Retail Ltd. (ABFRL) has built one of the most enviable portfolios in the Indian apparel space — not just by growing organically but by strategically acquiring some of the most iconic global and Indian brands. 📊 What makes ABFRL fascinating is its well-diversified brand pyramid: Luxury & Super Premium: Ralph Lauren, Galeries Lafayette, Ted Baker, Sabyasachi, Tarun Tahiliani, House of Masaba. Premium & Sub-Premium: Louis Philippe, Van Heusen, Allen Solly, American Eagle, Tasva, Jaypore. Mass & Value: Pantaloons, StyleUp. New-Age Digital (TMRW): The Indian Garage Co., Bewakoof, Berrylush, Natilene, Juneberry, Nobero, Veirdo, Urbano, and more. 👉 This strategy has positioned ABFRL to cover every wearing occasion and every consumer segment — Western wear (~70% of the market) as well as Ethnic wear (~30%). From luxury couture to everyday value fashion, ABFRL has become a one-stop powerhouse of brands that cater to India’s diverse and evolving consumer base. 💡 What’s more interesting is how M&A has been the backbone of this journey, enabling ABFRL to rapidly expand its brand mix and strengthen its presence across categories. 🔎 Now here’s a fun one — How many of these brands have you shopped from? Drop your number (or favorite brand) in the comments 👇 #ABFRL #Fashion #Retail #MergersAndAcquisitions #Luxury #Premium #EthnicWear #WesternWear #TMRW #DigitalFirst #Apparel #D2C #IndianFashion #BusinessStrategy #BrandBuilding

377

12 Comments